{{Rsnum
|rsid=12674093
|Gene=BBS9
|Chromosome=7
|position=33514550
|Orientation=plus
|GMAF=0.4242
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=BBS9
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 31.7 | 39.7 | 28.6
| HCB | 22.2 | 53.3 | 24.4
| JPT | 15.6 | 51.1 | 33.3
| YRI | 11.1 | 57.1 | 31.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 22.2 | 53.3 | 24.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12674093
|Name_s=
|Gene_s=BBS9
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109448
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12674093
|overall_frequency_n=69
|overall_frequency_d=128
|overall_frequency=0.539062
|n_genomes=44
|n_genomes_annotated=0
|n_haplomes=60
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}